Shots:

• The P-II KEYNOTE-890 study results involve assessing of Keytruda (200mg- IV) + TAVO (tavokinogene telseplasmid) in 25 patients with heavily pretreated- CT/radiotherapy refractory mTNBC who failed an average of 3.5 prior lines of CT
• The P-II KEYNOTE-890 study result:  @3mos. 20% + tumor reduction; two patients showed 66% tumor reduction including reduction of liver lesions; well tolerated
• OncoSec’s TAVO (tavokinogene telseplasmid) is an immunotherapy platform- allowing the intratumoral delivery of IL-12 and Keytruda (pembrolizumab) is mAb targeting PD-1- blocking the interaction b/w PD-1 and its ligands- PD-L1 and PD-L2 thus activating T-lymphocytes affecting both tumor & healthy cells

Ref: OncoSec | Image: OncoSec Medical Incorporated (ONCS)